Maravai’s cash balance decreased to $285 million as of the end of the first quarter of 2025 from $322 million at the end of 2024. This decrease primarily stems from a free cash flow deficit of about ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for ...

Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The Senate released a report revealing that Biden administration health officials were less than honest about the dangers associated with COVID-19 vaccines.

Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this ...

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology.